Literature DB >> 15019656

Risk factors and outcomes for 'vasoplegia syndrome' following cardiac transplantation.

John G Byrne1, Marzia Leacche, Subroto Paul, Tomislav Mihaljevic, James D Rawn, Stanton K Shernan, Gilbert H Mudge, Lynne W Stevenson.   

Abstract

OBJECTIVE: Vasoplegia syndrome after orthotopic heart transplantation (OHT) is a rare but highly lethal syndrome of unknown etiology, characterized by severe refractory hypotension, metabolic acidosis, and decreased systemic vascular resistance (SVR). The objective of this retrospective study was to identify the risk factors contributing to the development of vasoplegia syndrome after OHT in order to provide potential algorithms for its management.
METHODS: Between October 1992 and July 2001, 187 consecutive patients underwent OHT. Complete pre- and post-data were available in 147 patients (78%). Mean age was 49+/-11 years, 82% (120/147) were male, and donor ischemic time was 117+/-62 min. Twenty-eight of 147 (19%) developed vasoplegia syndrome, defined as SVR <800 dyns per cm(5) with serum bicarbonate <20 mEq/l.
RESULTS: Patients who developed vasoplegia syndrome demonstrated greater hospital mortality (25 vs. 9%, P=0.031) compared to those who did not. Multivariate logistic regression identified pre-operative use of intravenous heparin (OR 2.8, CI 1-7.4, P=0.039) and body surface area >1.9 m(2) (OR 7, CI 0.98-50, P=0.052) as independent predictors for the development of post-operative vasoplegia syndrome. Pre-operative use of inotropic support conferred protection against the development of post-operative vasoplegia syndrome (OR 0.25, CI 0.08-0.79, P=0.018). Pre-operative use of ACE inhibitors was not associated with increased risk (55 vs. 59%, P=0.441).
CONCLUSIONS: Vasoplegia syndrome following OHT is associated with high early mortality. The development of a risk stratification profile may help in patient selection as well as the post-operative management of vasoplegia syndrome following OHT.

Entities:  

Mesh:

Year:  2004        PMID: 15019656     DOI: 10.1016/j.ejcts.2003.11.032

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  16 in total

Review 1.  Transplantation of the failing Fontan.

Authors:  Amanda D McCormick; Kurt R Schumacher
Journal:  Transl Pediatr       Date:  2019-10

2.  Methylene Blue for Vasoplegic Syndrome After Cardiac Operation: Early Administration Improves Survival.

Authors:  J Hunter Mehaffey; Lily E Johnston; Robert B Hawkins; Eric J Charles; Leora Yarboro; John A Kern; Gorav Ailawadi; Irving L Kron; Ravi K Ghanta
Journal:  Ann Thorac Surg       Date:  2017-05-24       Impact factor: 4.330

3.  Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality.

Authors:  Lauren B Cooper; Robert J Mentz; Leah B Edwards; Amber R Wilk; Joseph G Rogers; Chetan B Patel; Carmelo A Milano; Adrian F Hernandez; Josef Stehlik; Lars H Lund
Journal:  J Heart Lung Transplant       Date:  2016-07-17       Impact factor: 10.247

4.  Etomidate use and postoperative outcomes among cardiac surgery patients.

Authors:  Chad E Wagner; Julian S Bick; Daniel Johnson; Rashid Ahmad; Xue Han; Jesse M Ehrenfeld; Jonathan S Schildcrout; Mias Pretorius
Journal:  Anesthesiology       Date:  2014-03       Impact factor: 7.892

5.  Improved survival after heart transplant for failed Fontan patients with preserved ventricular function.

Authors:  Jacob R Miller; Kathleen E Simpson; Deirdre J Epstein; Timothy S Lancaster; Matthew C Henn; Richard B Schuessler; David T Balzer; Shabana Shahanavaz; Joshua J Murphy; Charles E Canter; Pirooz Eghtesady; Umar S Boston
Journal:  J Heart Lung Transplant       Date:  2016-03-10       Impact factor: 10.247

Review 6.  Vasoplegia from Continuous Flow Left Ventricular Assist Devices.

Authors:  Shyama Sathianathan; Geetha Bhat; Robert Dowling
Journal:  Curr Cardiol Rep       Date:  2021-07-01       Impact factor: 2.931

7.  Pre-existing endothelial cell activation predicts vasoplegia after mitral valve surgery.

Authors:  Kirsten A Kortekaas; Jan H N Lindeman; Marlies E J Reinders; Meindert Palmen; Robert J M Klautz; Philip G de Groot; Mark Roest
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-06-04

8.  Pheochromocytoma crisis with severe cyclic blood pressure fluctuations in a cardiac pheochromocytoma patient successfully resuscitated by extracorporeal membrane oxygenation: a case report.

Authors:  Xiang Zhou; Dawei Liu; Longxiang Su; Yun Long; Wei Du; Qi Miao; Fang Li; Zhengyu Jin; Zhengpei Zeng; Ailun Luo; Yuguang Huang
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

9.  Vasoplegia following heart transplantation and left ventricular assist device explant is not associated with inferior outcomes.

Authors:  Jason M Ali; Serena Patel; Pedro Catarino; Alain Vuylsteke; Stephen Pettit; Sai Bhagra; Anna Kydd; Clive Lewis; Jayan Parameshwar; Pradeep Kaul; Catherine Sudarshan; Steven Tsui; David Jenkins; Yasir Abu-Omar; Marius Berman
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

10.  Vasoplegia after implantation of a continuous flow left ventricular assist device: incidence, outcomes and predictors.

Authors:  Eric E C de Waal; Bas van Zaane; Marnix M van der Schoot; Albert Huisman; Faiz Ramjankhan; Wilton A van Klei; Nandor Marczin
Journal:  BMC Anesthesiol       Date:  2018-12-08       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.